Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis

Table 4 Expression of prostate-specific membrane antigen in neovascularization of hepatocellular carcinoma and its relationship with clinicopathological parameters

Clinicopathological parameters	No. of cases	Tumor PSMA-positive, n				P value
		0	1	2	3
Gender
Male	185	25	27	52	81	0.912
Female	28	4	4	12	8
Age of diagnosis
< 50	106	12	14	29	51	0.331
≥ 50	107	17	17	35	38
Mean (range)	50 (19-85)
Region
Urban	131	15	16	44	56	0.080
Country	82	14	15	20	33
AFP
< 400	134	21	18	38	57	0.254
≥ 400	79	8	13	26	32
HBsAg
+	166	24	23	49	70	0.990
-	47	5	8	15	19
Tumor size
< 5 cm	92	14	10	23	45	0.552
≥ 5 cm	121	15	21	41	44
Stage
pT1	9	1	2	4	2	0.812
pT2	73	19	15	18	54
pT3	24	2	4	6	12
pT4	107	7	10	36	21
Nodal status
N0	190	27	24	58	82	0.466
N1	23	2	7	6	7
Metastasis
M0	188	23	31	57	77	0.136
M1	25	6	0	7	12
UICC stage at diagnosis
I-II	122	25	17	37	43	0.001a, r = 0.226
III-IV	91	4	14	27	46
Tumor grading
I	79	17	8	17	37	0.004a, r = 0.224
II	76	11	7	25	33
III	58	1	16	22	19
All case	213	29	31	64	89

^aP < 0.01. AFP: α-fetoprotein; HBsAg: Hepatitis B surface antigen; PSMA: Prostate-specific membrane antigen; r: Spearman r; UICC: Union for International Cancer Control.